US Broker Ratings

Zenas BioPharma, Inc. (ZBIO) Stock Analysis: A 54.59% Potential Upside Awaits Investors

Zenas BioPharma, Inc. (NASDAQ: ZBIO) is a compelling player in the biotechnology sector, with a focus on developing transformative immunology-based therapies. Headquartered in Waltham, Massachusetts, Zenas is making waves with..

REGENXBIO Inc. (RGNX): Investor Outlook with a Promising 225% Upside Potential

When it comes to the dynamic world of biotechnology, few companies spark as much interest as REGENXBIO Inc. (NASDAQ: RGNX). With its current market capitalization standing at $442.95 million and..

Definitive Healthcare Corp. (DH) Stock Analysis: Exploring a 152% Potential Upside Opportunity

Definitive Healthcare Corp. (NASDAQ: DH) is capturing the attention of investors with a striking 152.23% potential upside, as indicated by the average analyst target price. This substantial figure offers a..

MeiraGTx Holdings plc (MGTX): Investor Outlook with a Potential 249% Upside

MeiraGTx Holdings plc (NASDAQ: MGTX), a prominent player in the biotechnology sector, is capturing the attention of investors with its robust pipeline of genetic medicine therapies and an eye-catching potential..

Kamada Ltd. (KMDA) Stock Analysis: Unveiling a 45.9% Potential Upside in the Healthcare Sector

Investors eyeing opportunities within the healthcare sector may find Kamada Ltd. (NASDAQ: KMDA) to be a compelling option, particularly with its potential 45.9% upside. Based in Rehovot, Israel, Kamada operates..

Auna SA (AUNA) Stock Analysis: Healthcare Contender with a 35% Upside Potential

For investors with a keen eye on the healthcare sector, Auna SA (AUNA), a Luxembourg-based medical care facilities company, presents an intriguing proposition. Despite operating in a challenging market environment,..

Bicycle Therapeutics plc (BCYC) Investor Outlook: Exploring the 233% Potential Upside

For investors eyeing opportunities in the biotech sector, Bicycle Therapeutics plc (BCYC) offers a compelling story of innovation and potential growth. Headquartered in Cambridge, UK, this clinical-stage pharmaceutical company is..

Arbutus Biopharma Corporation (ABUS) Stock Analysis: Navigating a 22% Upside Potential Amidst Biotech Challenges

Arbutus Biopharma Corporation (NASDAQ: ABUS) is an intriguing player in the biotech sector, offering a mix of promise and challenges that could either pave the way for substantial returns or..

Personalis, Inc. (PSNL) Stock Analysis: Exploring a Promising 24.98% Upside with Innovative Cancer Genomics

Personalis, Inc. (NASDAQ: PSNL), a significant player in the healthcare sector, is making waves in the diagnostics and research industry with its cutting-edge cancer genomic tests. Based in Fremont, California,..

Bioventus Inc. (BVS) Stock Analysis: Unpacking a 63.66% Potential Upside

Bioventus Inc. (NASDAQ: BVS), a prominent player in the healthcare sector, is attracting investor attention with a compelling potential upside of 63.66%. As a medical device company headquartered in Durham,..

Treace Medical Concepts, Inc. (TMCI): Investor Outlook Reveals Potential 100% Upside

Treace Medical Concepts, Inc. (NASDAQ: TMCI), a prominent player in the medical devices industry, is attracting investor attention with its potential 100% upside. This Florida-based healthcare company specializes in innovative..

Humacyte, Inc. (HUMA) Stock Analysis: Unveiling a Potential 527% Upside with Innovative Biotech Solutions

Humacyte, Inc. (NASDAQ: HUMA), a pioneering company in the biotechnology sector, has captured investor interest with its groundbreaking approach to developing implantable, bioengineered human tissues. Despite the company’s current modest..

AtaiBeckley Inc. (ATAI): Unpacking the 233.90% Potential Upside in the Biotech Sector

AtaiBeckley Inc. (NASDAQ: ATAI), a clinical-stage biopharmaceutical company, has piqued the interest of investors with its remarkable potential upside of 233.90%, according to recent analyst ratings. With a current market..

Cullinan Therapeutics (CGEM) Stock Analysis: Exploring a 101% Upside Potential

Cullinan Therapeutics, Inc. (NASDAQ: CGEM) is positioned at the intersection of biotechnology innovation and investor curiosity. With a market capitalization of $898.55 million, this clinical-stage biopharmaceutical company is drawing significant..

Tyra Biosciences, Inc. (TYRA) Stock Analysis: 48.56% Upside Potential Amid Strong Buy Ratings

Tyra Biosciences, Inc. (NASDAQ: TYRA), a pioneering player in the biotechnology sector, is capturing investor attention with its remarkable growth potential and a significant upside forecasted by analysts. With a..

Sana Biotechnology (SANA) Stock Analysis: Exploring a Potential 104% Upside with Innovative Cell Therapies

Sana Biotechnology, Inc. (NASDAQ: SANA) has captured the attention of investors with its promise of revolutionary advancements in cell engineering, bringing hope to areas of medicine with significant unmet needs...

Ardelyx, Inc. (ARDX) Investor Outlook: Analysts See a Potential 142% Upside

Ardelyx, Inc. (NASDAQ: ARDX) is making waves in the biotechnology sector with its innovative approach to addressing unmet medical needs. With a focus on developing and commercializing therapeutic drugs for..

Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: Uncovering a 57% Upside Potential in Biotech

Oric Pharmaceuticals, Inc. (NASDAQ: ORIC) has been making waves in the biotechnology sector with its innovative approach to tackling cancer resistance mechanisms. With a market capitalization of $1.31 billion, the..

Kura Oncology, Inc. (KURA): Investor Outlook Reveals 275% Upside Potential

Kura Oncology, Inc. (NASDAQ: KURA) stands out in the biotechnology sector, with its market capitalization of $752.7 million and a focus on developing innovative cancer treatments. Headquartered in San Diego,..

Prothena Corporation plc (PRTA) Stock Analysis: Navigating a 137% Potential Upside in the Biotech Sector

Prothena Corporation plc (NASDAQ: PRTA) stands as a noteworthy player in the biotechnology sector, a field that often captures investor interest due to its high-risk, high-reward profile. With its headquarters..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds